Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: The OITA-GF study 2

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Tamura, Akira ^a   Murakami, Kazunari ^a   Kadota, Junichi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Aspirin; Famotidine; Gastroduodenal erosion; Gastroduodenal ulcer; Lansoprazole

Indexed keywords

ACETYLSALICYLIC ACID; ANTIULCER AGENT; FAMOTIDINE; LANSOPRAZOLE; STEROID;

AGED; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; ENDOSCOPY; FEMALE; GASTRIC MUCOSA; HUMAN; MALE; MIDDLE AGED; PEPTIC ULCER; PREVALENCE; ARTICLE; DRUG EFFECT; STOMACH MUCOSA;

AGED; ANTI-ULCER AGENTS; ASPIRIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; ENDOSCOPY; FAMOTIDINE; FEMALE; GASTRIC MUCOSA; HUMANS; LANSOPRAZOLE; MALE; MIDDLE AGED; PEPTIC ULCER; PREVALENCE; STEROIDS;

EID: 84875293018     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-116     Document Type: Article

References (24)

1. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on practice guidelines: developed in collaboration with the Canadian cardiovascular society endorsed by the American academy of family physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevationmyocardial infarction, writing on behalf of the 2004 writing committee. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW, 2004 Writing Committee Members, Circulation 2008 2008 117 296 329
2. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons, endorsed by the American association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B, J Am Coll Cardiol 2007 50 1 e157 17692738
3. Prophylactic aspirin and risk of peptic ulcer bleeding. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P, BMJ 1995 310 827 830 10.1136/bmj.310.6983.827 7711618
4. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH, Am J Gastroenterol 2000 95 2218 2224 11007221
5. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiology foundation task force on clinical expert consensus documents. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Circulation 2008 118 1894 1909 18836135
6. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Taha AS, McCloskey C, Prasad R, Bezlyak V, Lancet 2009 374 119 125 10.1016/S0140-6736(09)61246-0 19577798
7. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. Nishino M, Sugimoto M, Kodaira C, Yamade M, Uotani T, Shirai N, Ikuma M, Tanaka T, Sugimura H, Hishida A, Furuta T, J Clin Pharmacol 2011 51 1079 1086 10.1177/0091270010376194 20663999
8. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, Kng C, Yuen WC, Lau YK, Kwan A, Wong BC, Gastroenterology 2010 138 82 88 10.1053/j.gastro.2009.09.063 19837071
9. Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin? Holtmann G, Gschossmann J, Buenger L, Gerken G, Talley NJ, Gastroenterology 2002 123 1451 1458 10.1053/gast.2002.36556 12404219
10. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ, Aliment Pharmacol Ther 2005 22 795 801 10.1111/j.1365-2036.2005.02649.x 16225488
11. Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. Tamura A, Murakami K, Kadota J, OITA-GF Study Investigators, QJM 2011 104 133 139 10.1093/qjmed/hcq169 20870780
12. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I, Scand J Gastroenterol 1993 28 681 687 10.3109/00365529309098272 8210982
13. Highly sensitive urine-based enzyme-linked immunosorbent assay for detection of antibody to Helicobacter pylori. Katsuragi K, Noda A, Tachikawa T, Azuma A, Mukai F, Murakami K, Fujioka T, Kato M, Asaka M, Helicobacter 1998 3 289 295 10.1046/j.1523-5378.1998.08045.x 9844071
14. Clinical usefulness of urine-based enzyme-linked immunosorbent assay for detection of antibody to Helicobacter pylori: a collaborative study in nine medical institutions in Japan. Kato M, Asaka M, Saito M, Sekine H, Ohara S, Toyota T, Akamatsu T, Kaneko T, Kiyosawa K, Nishizawa O, Kumagai T, Katsuyama T, Abe M, Kosaka M, Hariya S, Minami K, Sanai Y, Sawamura M, Tachikawa T, Helicobacter 2000 5 109 119 10.1046/j.1523-5378.2000.00017.x 10849061
15. Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE-famotidine or rebamipide in comparison by endoscopy). Yamao J, Kikuchi E, Matsumoto M, Nakayama M, Ann T, Kojima H, Mitoro A, Yoshida M, Yoshikawa M, Yajima H, Miyauchi Y, Ono H, Akiyama K, Sakurai G, Kinoshita Y, Haruma K, Takakura Y, Fukui H, J Gastroenterol 2006 41 1178 1185 17287897
16. Role of gastric acid in aspirin-induced gastric irritation in the rat. Brodie DA, Chase BJ, Gastroenterology 1967 53 604 610 6047921
17. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Nishino M, Sugimoto M, Kodaira C, Yamade M, Shirai N, Ikuma M, Tanaka T, Sugimura H, Hishida A, Furuta T, Dig Dis Sci 2010 55 1627 1636 10.1007/s10620-009-0920-3 19672708
18. Progress with proton pump inhibition. Bell NJ, Hunt RH, Yale J Biol Med 1992 65 649 657 1341069
19. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Nauclér E, Svedberg LE, Heart 2011 97 797 802 10.1136/hrt.2010.217547 21415072
20. Subepithelial hemorrhages and erosions of human stomach. Laine L, Weinstein WM, Dig Dis Sci 1988 33 490 503 10.1007/BF01536037 3280275
21. The national ASGE survey on upper gastrointestinal bleeding. II. Clinical prognostic factors. Silverstein FE, Gilbert DA, Tedesco FJ, Buenger NK, Persing J, Gastrointest Endosc 1981 27 80 93 10.1016/S0016-5107(81)73156-0 6971776
22. The safety and clinical utility of esophagogastroduodenoscopy for acute gastrointestinal bleeding after myocardial infarction: a six-year study of 42 endoscopies in 34 consecutive patients at two university teaching hospitals. Cappell MS, Am J Gastroenterol 1993 88 344 350 8438838
23. Clinical significance and outcome of gastric mucosal erosions: a long-term follow-up study. Toljamo KT, Niemelä SE, Karttunen TJ, Karvonen AL, Lehtola JK, Dig Dis Sci 2006 51 543 537 10.1007/s10620-006-3168-1 16614965
24. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E, Rofecoxib Osteoarthritis Endoscopy Multinational Study Group, Aliment Pharmacol Ther 2001 15 1593 1601 10.1046/j.1365-2036.2001.01007.x 11563999